President Donald Trump disclosed a stock purchase in Corcept Therapeutics (NASDAQ: CROT) on March 4, just before the pharmaceutical company received key Food and Drug Administration (FDA) support.
Since then, Corcept’s shares have surged roughly 168% and trade at $95.65 at press time, July 22, following the major regulatory catalyst for the company’s business and more recently tariff-related developments.
As a result, the Trump’s March 4 $15,001-50,000 position is now worth approximately $40,000-134,000.
The surge, which has pushed Corcept’s market capitalization to around $10.2 billion, was further boosted by Trump’s announcement of a temporary extension of the zero-tariff policy on generic drugs.
According to a July 21 post on Truth Social, the policy is designed to encourage pharmaceutical companies to shift generic drug manufacturing to the United States, which sparked a broad rally across pharmaceutical stocks.
“This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them. The objective of this Policy is to protect the people of the United States,” the president said.
Corcept Therapeutics stock rises amid regulatory advancements
Corcept Therapeutics has also taken further steps to advance its drug pipeline, including the resubmission of its New Drug Application (NDA) to the FDA for relacorilant, a potential treatment for patients with Cushing’s syndrome.
The resubmission follows an FDA request for additional analyses of data from the company’s original application. Corcept expects the agency’s review process to take approximately six months.
Moreover, the company also highlighted positive clinical trial results at the American Society of Clinical Oncology (ASCO) annual meeting. According to the results, the combination therapy reduced the risk of death by 35% compared with nab-paclitaxel alone.
Financially, Corcept reported first-quarter 2026 revenue of approximately $165 million, below analyst expectations of $186 million. Despite the revenue miss, however, analysts remain optimistic about the company’s outlook, with the Wall Street consensus currently sitting at “Buy,” as per TipRanks data.
Featured image via Shutterstock
